Board changes: Eisenberg resigns, co-founder Brown appointed director

908 Devices Inc.

Marcia Eisenberg resigned from board and compensation committee effective June 12, 2025.
Eisenberg's resignation follows the company's sale of its bioprocessing product portfolio.
Co-founder Christopher D. Brown appointed to board as Class III director term expiring at 2026 annual meeting.
Brown is currently VP Analytics R&D at Repligen (RGEN), which purchased 908's bioprocessing portfolio.
Brown waived initial compensation under the non-employee director policy; continues consulting agreement.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher D. Brown

Director

MASS · 908 Devices Inc.

Effective: 2025-06-13
Filed: Jun 16, 2025 23:59 UTC

On June 13, 2025, Christopher D. Brown was appointed to the Board to fill the vacancy created following Ms. Eisenberg’s resignation.

Departed

Marcia Eisenberg

Director

MASS · 908 Devices Inc.

Effective: 2025-06-12
Successor: Christopher D. Brown
Filed: Jun 16, 2025 23:59 UTC

On June 12, 2025, Marcia Eisenberg resigned from the Board of Directors (the “Board”) of 908 Devices Inc. (the “Company”) and the Compensation Committee of the Board. Her resignation was effective on June 12, 2025 at 5:00 p.m. Eastern Time.

Source: SEC EDGAR

accession 0001104659-25-059685

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.